Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
225 hedge funds and large institutions have $8B invested in Mirati Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 68 increasing their positions, 83 reducing their positions, and 24 closing their positions.
104% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 24
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
45% more capital invested
Capital invested by funds: $5.53B → $8B (+$2.47B)
13% more funds holding
Funds holding: 200 → 225 (+25)
18% less repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 83
20% less call options, than puts
Call options by funds: $150M | Put options by funds: $187M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$90.9M |
| 2 |
AG
Artal Group
Luxembourg
|
+$68.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$66.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$58.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$56.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$115M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$91.9M |
| 3 |
Jennison Associates
New York
|
-$57.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$34.8M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$30.8M |
MRTX Hedge Fund Activity: Q3 2020 in Review
225 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2020, worth a combined $8B — up 45% from $5.53B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new MRTX positions and 24 closed out — a net gain of 25 holders — while 68 added to existing stakes and 83 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $90.9M. The largest seller was Sands Capital Management, cutting an estimated $115M.
- 225 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2020, up from 200 in Q2 2020.
- Funds reported $8B of Mirati Therapeutics, Inc. Common Stock stock for Q3 2020, up 45% quarter-over-quarter.
- 49 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2020 and 24 closed out, a net change of +25 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2020 was Perceptive Advisors, an estimated $90.9M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2020 was Sands Capital Management, an estimated $115M sold.
Based on aggregated 13F filings for Q3 2020.